Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2019, Vol. 15 ›› Issue (06): 605 -611. doi: 10.3877/cma.j.issn.1673-5250.2019.06.001

Special Issue:

Forums

Pathological and molecular diagnosis of epithelial ovarian cancer

Qianying Zhao1, Mingrong Qie1,()   

  1. 1. Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2019-01-09 Revised:2019-05-02 Published:2019-12-01
  • Corresponding author: Mingrong Qie
  • About author:
    Corresponding author: Qie Mingrong, Email:
  • Supported by:
    National Natural Science Foundation of China(61741511)

Epithelial ovarian cancer (EOC) is categorized into two pathological subtypes, such as EOC Ⅰ and Ⅱ subtype, with distinct origins and malignant phenotypes. However, EOC presents heterogeneity in diverse aspects like pathological morphology, clinical feature, molecular phenotype, etc.. With increasing data based on second-generation gene sequencing technology, we have deepened our understanding of the biological behaviors of EOC. The comprehensive diagnosis of pathological and molecular characteristics may provide more efficient and accurate screening and treatment strategies for EOC. This paper focuses on the development of EOC′s pathological and molecular diagnosis mechanism and the technology of molecular diagnosis, as well as the latest research progress in the application of EOC screening and treatment.

[1]
Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis[J]. Am J Pathol, 2004, 164(5): 1511-1518.
[2]
Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary[J]. Obstet Gynecol, 2010, 116(2): 269-273.
[3]
Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded[J]. Am J Pathol, 2016, 186(4): 733-747.
[4]
Kurman RJ, Carcangiu ML, Herrington S, et al. WHO classification of tumours of female reproductive organs[M]. 4th ed. Lyon, France: IARC, 2014: 15-23.
[5]
Blagden SP. Harnessing pandemonium: the clinical implications of tumor heterogeneity in ovarian cancer[J]. Front Oncol, 2015, 5: 149.
[6]
Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma[J]. Ann Oncol, 2013, 24(Suppl 10): x16-x21.
[7]
Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: shifting the paradigm[J]. Hum Pathol, 2011, 42(7): 918-931.
[8]
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma[J]. Nature, 2011, 474(7353): 609-615.
[9]
Vang R, Levine DA, Soslow RA, et al. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study[J]. Int J Gynecol Pathol 2016, 35(1): 48-55.
[10]
Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian fallopian tube, and peritoneal carcinomas[J]. Clin Cancer Res, 2014, 20(3): 764-775.
[11]
Beltrame L, Di Marino M, Fruscio R, et al. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study[J]. Ann Oncol, 2015, 26(7): 1363-1371.
[12]
Rojas V, Hirshfield KM, Ganesan S, et al. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment [J]. Int J Mol Sci, 2016, 17(12): e2113.
[13]
Bashashati A, Ha G, Tone A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling[J]. J Pathol, 2013, 231(1): 21-34.
[14]
Castellarin M, Milne K, Zeng T, et al. Clonal evolution of high-grade serous ovarian cancer from primary to recurrent disease[J]. J Pathol, 2013, 229(4): 515-524.
[15]
Cowin PA, George J, Fereday S, et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin[J]. Cancer Res, 2012, 72(16): 4060-4073.
[16]
Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer[J]. Nature, 2015, 521(7553): 489-494.
[17]
Schwarz RF, Ng CK, Cooke SL, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis[J]. PLoS Med, 2015, 12(2): e1001789.
[18]
Lambrechts S, Smeets D, Moisse M, et al. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer[J]. Eur J Cancer, 2016, 53: 51-64.
[19]
Ruiz A, Llort G, Yagüe C, et al. Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing[J]. Biomed Res Int, 2014, 2014, 542541.
[20]
Bentley DR. Whole-genome re-sequencing[J]. Curr Opin Gene Dev, 2006, 16(6): 545-552.
[21]
Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry[J]. Nature, 2008, 456(7218): 53-59.
[22]
Harismendy O, Ng PC, Strausberg RL, et al. Evaluation of next generation sequencing platforms for population targeted sequencing studies[J]. Genome Biol, 2009, 10(3): R32.
[23]
Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome[J]. JAMA, 2011, 305(22): 2304-2310.
[24]
Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer[J]. Nat Genet, 2011, 43(9): 879-882.
[25]
Pelttari LM, Heikkinen T, Thompson D, et al. RAD51C is a susceptibility gene for ovarian cancer[J]. Hum Mol Genet, 2011, 20(16): 3278-3288.
[26]
Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer[J]. Nat Genet, 2011, 43(11): 1104-1107.
[27]
Turnbull C, Sud A, Houlston RS. Cancer genetics, precision prevention and a call to action [J]. Nat Genet, 2018, 50(9): 1212-1218.
[28]
Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer - molecular characteristics and clinical implications[J]. Gynecol Oncol, 2014, 132(2): 506-512.
[29]
Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations[J]. Gastroenterology, 2008, 135(2): 419-428.
[30]
Tan TZ, Miow QH, Huang RY, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer[J]. EMBO Mol Med, 2013, 5(7): 1051-1066.
[31]
Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome[J]. Clin Cancer Res, 2008, 14(16): 5198-5208.
[32]
Konecny GE, Wang C, Hamidi H, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer[J]. J Natl Cancer Inst, 2014, 106(10): dju249.
[33]
Barrett CL, DeBoever C, Jepsen K, et al. Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy[J]. Proc Natl Acad Sci USA, 2015, 112(23): E3050-E3057.
[34]
Buys SS, Partridge E, Black A, et al. Effect on screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial[J]. JAMA, 2011, 305(22): 2295-2303.
[35]
Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up[J]. Gynecol Oncol, 2016, 143(2): 270-275.
[36]
Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (ULCTOCS): a randomized controlled trial[J]. Lancet, 2016, 387(10022): 945-956.
[37]
Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases[J]. Cancer, 2005, 104(12): 2807-2816.
[38]
Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing[J]. Proc Natl Acad Sci USA, 2011, 108(44): 18032-18037.
[39]
Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group[J]. J Clin Oncol, 2012, 30(21): 2654-2663.
[40]
Møller P, Hagen AI, Apold J, et al. Genetic epidemiology of BRCA mutations: family history detects less than 50% of the mutation carriers[J]. Eur J Cancer, 2007, 43(11): 1713-1717.
[41]
Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes [J]. J Clin Oncol, 2006, 24(28): 4642-4660.
[42]
Ross JS, Ali SM, Wang K, et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies[J]. Gynecol Oncol, 2013, 130(3): 554-559.
[43]
Greaves M, Maley C. Clonal evolution in cancer[J]. Nature, 2012, 481(7381): 306-313.
[44]
Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding [J]. Nat Med, 2015, 21(5): 440-448.
[45]
US Food and Drug Administration. FDA approves bevacizumab in combination with chemotherapy for ovarian cancer[EB/OL]. (2018-06-13) [2018-12-25].

URL    
[46]
US Food and Drug Administration. FDA approves olaparib tablets for maintenance treatment in ovarian cancer[EB/OL]. (2017-08-17) [2018-12-25].

URL    
[47]
European Medicines Agency. EU/3/03/171[EB/OL]. (2003-10-17)[2018-12-25].

URL    
[48]
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer [J]. J Clin Oncol, 2012, 30(17): 2039-2045.
[49]
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13): 1302-1308.
[50]
Secord AA, Nixon AB, Hurwitz HI. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 135(2): 349-358.
[51]
Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies[J]. Ann Oncol, 2014, 25(1): 32-40.
[52]
Liu JF, Matulonis UA. What is the place of PARP inhibitors in ovarian cancer treatment?[J]. Curr Oncol Rep, 2016, 18(5): 29.
[53]
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer[J]. N Engl J Med, 2016, 375(22): 2154-2164.
[54]
Ryland GL, Hunter SM, Doyle MA, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors[J]. Genome Med, 2015, 7(1): 87.
[55]
Mackenzie R, Kommoss S, Winterhoff BJ, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms[J]. BMC Cancer, 2015, 15: 415.
[56]
Lim SM, Park HS, Kim S, et al. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus[J]. Oncotarget, 2016, 7(9): 10547-10556.
[57]
Duffy MJ, Synnott NC, McGowan PM, et al. P53 as a target for the treatment of cancer[J]. Cancer Treat Rev, 2014, 40(10): 1153-1160.
[58]
Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis[J]. Cell Death Differ, 2011, 18(12): 1904-1913.
[59]
Farley J, Brady W, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2013, 14(2): 134-140.
[1] Gang Zhang, Yong Qin, Chao Huang, Zhen Xue, Songcen Lyu. Emerging therapeutic targets based on phenotypic transformation of osteoarthritic chondrocytes[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(03): 352-362.
[2] Yang Liu, Zhaoying Sheng, Linlin Sun. Interleukin-6 promoter reduces cellular inflammation and DNA damage by regulating human telomerase reverse transcriptase[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(02): 104-110.
[3] Shuqin Zhang, Lian Chen. Diagnosis and treatment of postpartum intrauterine retained products of conception[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 493-497.
[4] Qin Liu, Hanmin Liu, Liang Xie. Current status of research on the role of matrix metalloproteinases in the pathogenesis of childhood asthma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 564-568.
[5] Jiechun Shi, Ziyu Fan, Yan Xing. Early warning efficiency of different screening methods on cervical adenocarcinoma in situ[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 575-581.
[6] Dan Tang, Xiaoxi Yao, Bowen Yang, Shaolong Xue, Mengyao Li, Liuxing Wei, Mingrong Xi. The impact of doublecortin-like kinase 1 on the clinical characteristics of endometrioid adenocarcinoma patients[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 582-590.
[7] Yi Wei, Yuxi Zhou, Ye Yang, Xiufeng Ling, Chun Zhao. Current research status on roles of microRNA on endometrial receptivity[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 266-270.
[8] Lin Lin, Simeng Tian, Yonghua Yu, Feifei Xu, Mingli Huang. Current research status on treatment of intrauterine adhesion by stem cells and their exosomes[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 271-275.
[9] Xin Li, Yi Wei, Juan Zhang, Juanjuan Zhang, Xiufeng Ling, Chun Zhao, Mianqiu Zhang. Influencing factors on clinical pregnancy outcomes of frozen-thaw embryo transfer cycle in women of advanced age[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 276-283.
[10] Lin Yang, Rutie Yin. Current research status on etiology and treatment of patients with white lesions of vulva[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 157-165.
[11] Qing Liu, Zhiling Wang. Gut mycobiome and pediatric inflammatory bowel disease[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 172-178.
[12] Xueling Zhang, Weibin Chen, Wenshuo Wei, Ming Chen, Hongwei Zhu. Clinical features and therapeutic effects of Noonan syndrome[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 192-199.
[13] Weicong Gao, Li Li, Zhonghua Zhang, Xianghui Zhu, Suqiao Liu. Impact of impaired glucose regulation on recurrence within 2 years after modified radical surgery in patients with cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 231-237.
[14] Siping Hu, Xingyu Xiong, Hang Xu, Lu Yang. The mechanisms of senescence-associated secretory phenotype factors in the occurrence and progression of prostate cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 425-434.
[15] Qile Shen, Qinhua Zhao, Sugang Gong, Jinming Liu, Lan Wang, Hongling Qiu. Relationship between serum CC16 protein expression, lung function and emphysema phenotype in stable COPD patients[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(05): 690-695.
Viewed
Full text


Abstract